Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating JNJ-42160443 for neuropathic pain conditions including postherpetic neuralgia and post-traumatic neuralgia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Neuralgia
• Postherpetic Neuralgia

Drugs mentioned

• JNJ-42160443

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Pain, Neuralgia, Postherpetic | Phase 2 | Status: TERMINATED